EICHORCondition: B-Cell Non-Hodgkin Lymphoma · Relapsed B-Cell Non-Hodgkin Lymphoma · Refractory B-Cell Non-Hodgkin Lymphoma · Sponsor: ADC Therapeutics S.A.
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of California San Francisco - Fresno Center for Medical Education and Research | Clovis, California, United States | — |
| Scripps Health - Prebys Cancer Center | San Diego, California, United States | — |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | — |
| Miami Cancer Institute | Miami, Florida, United States | — |
| Memorial Cancer Institute - Memorial Hospital West | Pembroke Pines, Florida, United States | — |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | — |
| The Blood and Marrow Transplant Group of Georgia | Atlanta, Georgia, United States | — |
| Mission Cancer + Blood - Mission Cancer Foundation | Des Moines, Iowa, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| University of Minnesota | Minneapolis, Minnesota, United States | — |
| Columbia University Irving Medical Center | New York, New York, United States | — |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04970901